Renate Starr
YOU?
Author Swipe
Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: Interim clinical experience demonstrating feasibility and safety Open
A challenge in treating glioblastoma (GBM) is its phenotypic heterogeneity between patients and within tumors. Chlorotoxin (CLTX), a peptide from scorpion venom, broadly binds glioma cells through a mechanism involving surface matrix metal…
View article: Overcoming myeloid-driven resistance to CAR T therapy by targeting SPP1
Overcoming myeloid-driven resistance to CAR T therapy by targeting SPP1 Open
Chimeric antigen receptor (CAR) T cell therapy faces notable limitations in treatment of solid tumors. The suppressive tumor microenvironment (TME), characterized by complex interactions among immune and stromal cells, is gaining recogniti…
View article: TMIC-42. CONQUERING SPP1+ MYELOID-DRIVEN RESISTANCE OF GLIOBLASTOMA TO IL13RA2-TARGETED CAR T CELL THERAPY
TMIC-42. CONQUERING SPP1+ MYELOID-DRIVEN RESISTANCE OF GLIOBLASTOMA TO IL13RA2-TARGETED CAR T CELL THERAPY Open
In the evolving landscape of glioblastoma (GBM) therapy, the recent proliferation of clinical trials exploring chimeric antigen receptor (CAR) T cell interventions has garnered attention, although their therapeutic efficacy remains limited…
View article: Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial
Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial Open
Chimeric antigen receptor T cell (CAR-T) therapy is an emerging strategy to improve treatment outcomes for recurrent high-grade glioma, a cancer that responds poorly to current therapies. Here we report a completed phase I trial evaluating…
View article: Targeting Wnt signaling for improved glioma immunotherapy
Targeting Wnt signaling for improved glioma immunotherapy Open
Introduction Despite aggressive standard-of-care therapy, including surgery, radiation, and chemotherapy, glioblastoma recurrence is almost inevitable and uniformly lethal. Activation of glioma-intrinsic Wnt/β-catenin signaling is associat…
View article: 1520 Phase I trial evaluating locoregionally-delivered IL13Rα2-targeting CAR T cells in high-grade glioma
1520 Phase I trial evaluating locoregionally-delivered IL13Rα2-targeting CAR T cells in high-grade glioma Open
Background Chimeric antigen receptor (CAR) T cell therapy is being explored in early-stage clinical trials as a strategy to improve treatment outcomes for high-grade gliomas (HGGs). We report here, a completed phase I trial (NCT02208362) e…
View article: 580 Mapping interstitial fluid flow in the brain to improve CAR T cell trafficking and efficacy
580 Mapping interstitial fluid flow in the brain to improve CAR T cell trafficking and efficacy Open
Background A major obstacle to successful CAR T cell therapy for glioblastoma (GBM) is effective tumor trafficking and infiltration, which is limited by the blood-brain and blood-CSF barriers. Further, the GBM tumor microenvironment (TME) …
View article: 1525 Initial clinical experience with chlorotoxin-redirected CAR T cells for patients with recurrent glioblastoma
1525 Initial clinical experience with chlorotoxin-redirected CAR T cells for patients with recurrent glioblastoma Open
Background IgE-producing multiple myeloma, non-Hodgkin's lymphoma and chronic B cell leukemia are caused by neoplasm of IgE-producing B cells. Several chimeric antigen receptor (CAR) T-cell therapies have been approved for treating B cell …
View article: Phase I Trial Evaluating Locoregionally-delivered IL13Rα2-targeting CAR T Cells in High-Grade Glioma
Phase I Trial Evaluating Locoregionally-delivered IL13Rα2-targeting CAR T Cells in High-Grade Glioma Open
Chimeric antigen receptor (CAR) T cell therapy is at early stages of clinical testing for solid tumors. We report here a completed phase I trial (NCT02208362) evaluating locoregional delivery of IL13Rα2-targeted CAR T cells in 65 patients …
View article: Supplemental Figure Legends from IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype
Supplemental Figure Legends from IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype Open
Legends for Supplemental Figures 1-9 and Supplemental Table 1
View article: Supplementary Data from IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype
Supplementary Data from IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype Open
Supp Fig 1 Compares IL2 alone to manufacturing platform. Supp Fig 2 Product post-enrichment. Supp Fig 3 Additional characterization of IL2 and IL15 cultured CAR-T cells. Supp Fig 4 Heat map comparing CD4 gene expression differences in IL2 …
View article: Data from IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype
Data from IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype Open
Improvements in the quality and fitness of chimeric antigen receptor (CAR)-engineered T cells, through CAR design or manufacturing optimizations, could enhance the therapeutic potential of CAR-T cells. One parameter influencing the effecti…
View article: Data from IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype
Data from IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype Open
Improvements in the quality and fitness of chimeric antigen receptor (CAR)-engineered T cells, through CAR design or manufacturing optimizations, could enhance the therapeutic potential of CAR-T cells. One parameter influencing the effecti…
View article: Supplementary Data from IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype
Supplementary Data from IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype Open
Supp Fig 1 Compares IL2 alone to manufacturing platform. Supp Fig 2 Product post-enrichment. Supp Fig 3 Additional characterization of IL2 and IL15 cultured CAR-T cells. Supp Fig 4 Heat map comparing CD4 gene expression differences in IL2 …
View article: Supplemental Figure Legends from IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype
Supplemental Figure Legends from IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype Open
Legends for Supplemental Figures 1-9 and Supplemental Table 1
View article: Data from CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies
Data from CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies Open
Glioblastoma (GBM) contains self-renewing GBM stem cells (GSC) potentially amenable to immunologic targeting, but chimeric antigen receptor (CAR) T-cell therapy has demonstrated limited clinical responses in GBM. Here, we interrogated mole…
View article: Supplementary Table 1 from IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity
Supplementary Table 1 from IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity Open
Supplementary Table 1
View article: Supplementary Table 1 from IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity
Supplementary Table 1 from IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity Open
Supplementary Table 1
View article: Data from IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity
Data from IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity Open
Chimeric antigen receptor (CAR) T cells mediate potent antigen-specific antitumor activity; however, their indirect effects on the endogenous immune system are not well characterized. Remarkably, we demonstrate that CAR T-cell treatment of…
View article: Data from IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity
Data from IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity Open
Chimeric antigen receptor (CAR) T cells mediate potent antigen-specific antitumor activity; however, their indirect effects on the endogenous immune system are not well characterized. Remarkably, we demonstrate that CAR T-cell treatment of…
View article: Supplementary Table 2 from IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity
Supplementary Table 2 from IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity Open
Supplementary Table 2
Supplementary Table 2 from IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity Open
Supplementary Table 2
Supplementary Table 1 from CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies Open
CRISPR screening reads on CAR T cells and GSCs
Supplementary Data from CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies Open
Supplementary Methods, Figures S1-S14, Table legends, and References
Supplementary Table 2 from CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies Open
CAR T cell targets from CRISPR screening that are shared between two donors
Supplementary Data from CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies Open
Supplementary Methods, Figures S1-S14, Table legends, and References
Supplementary Table 1 from CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies Open
CRISPR screening reads on CAR T cells and GSCs
Supplementary Figures from IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity Open
Supplementary Figures S1-S19
Supplementary Figures from IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity Open
Supplementary Figures S1-S19